Atea Pharmaceuticals, Inc. (AVIR) SEC Filings & Earnings Calls

No approved products or revenue

“We have no products that have generated any commercial revenue and we may not again achieve or maintain profitability.” · word for word

Significant accumulated deficit

“Accumulated deficit $(600,942) as of June 30, 2026.”

Dependence on single lead candidate

“Our business is highly dependent on the success of our lead product candidate, the fixed-dose combination of bemnifosbuvir and ruzasvir for the treatment of HCV infection.” · word for word

Competition from established HCV therapies

“In 2025, global net sales of branded HCV therapeutics known in the US as Epclusa® (including the authorized generic copy of Epclusa®) and Mavyret® exceeded $2.5 billion with the US accounting for approximately 50% of these sales.” · word for word

Milestone payment obligations

“The next potential milestone under the Merck License Agreement, in the amount of $10,000, is payable upon the acceptance by the FDA of a NDA covering a product candidate including ruzasvir.” · word for word

Clinical-stage biotech with no approved products; reliance on Phase 3 success for BEM/RZR.

“Company is late-stage clinical; BEM/RZR is lead candidate; C-FORWARD results pending.”

Cash burn rate; cash decreased from $301.8M to $219.5M in six months.

“Cash and Investments decreased from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026.”

Clinical trial risk: Phase 3 HCV results pending; failure could impair pipeline value.

“Topline results for C-BEYOND expected mid-2026 and C-FORWARD around year-end 2026.”

Cash burn: Cash decreased by $45.8M in Q1 2026; runway limited without revenue.

“Cash $256.0M at March 31, 2026 vs $301.8M at December 31, 2025.”

Clinical trial failure risk

“Our business is highly dependent on the success of our lead product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection.” · word for word

Cash runway risk

“We may require substantial additional financing, which may not be available on acceptable terms, or at all.” · word for word

Regulatory approval risk

“The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable.”

Competition risk

“Competing HCV treatments exist; market is competitive.”

Clinical trial failure risk

“Our business is highly dependent on the success of our lead product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection.”

Regulatory approval uncertainty

“The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable.”

No approved products or revenue

“We have no products that have generated any commercial revenue and we may not again achieve or maintain profitability.” · word for word

Significant operating losses and accumulated deficit

“We have incurred significant operating expenses since inception. We expect our expenditures will increase for the foreseeable future.” · word for word

Dependence on clinical trial success for HCV regimen

“Our business is highly dependent on the success of our lead product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection.” · word for word

Need for additional financing

“We may require substantial additional financing, which may not be available on acceptable terms, or at all.” · word for word

Regulatory approval uncertainty

“The regulatory approval processes of the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities are lengthy, expensive, time-consuming and inherently unpredictable.” · word for word

Clinical trial risk: topline results pending; regulatory approval uncertain.

“Phase 3 results expected mid-2026 and year-end 2026.”

Clinical trial risk: Phase 3 HCV results may not meet endpoints; HEV program is early stage.

“Phase 3 topline results expected mid-2026; HEV Phase 1 initiation mid-2026.”

Clinical-stage biopharmaceutical company with no approved products

“We have a limited operating history and no history of successfully developing or commercializing any approved antiviral products.” · word for word

Dependence on single product candidate

“Our business is highly dependent on the success of our product candidate, the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV infection.” · word for word

Significant operating losses and negative cash flow

“We have incurred significant operating expenses since inception. We expect our expenditures will increase for the foreseeable future. We have no products that have generated any commercial revenue and we may not again achieve or maintain profitability.” · word for word

Need for substantial additional financing

“We may require substantial additional financing, which may not be available on acceptable terms, or at all.” · word for word

Clinical trial risks

“Clinical development, including enrollment of patients in clinical trials, is an expensive, lengthy and uncertain process.” · word for word

Clinical-stage biopharma with no approved products; reliance on pipeline success.

“Clinical-stage biopharmaceutical company; no revenue from product sales.”